Skip to content

K-Stock Briefing

https://kstockbriefing.com

  • About Us
  • Weekly News
  • IR Room
  • RESEARCH
    • Semiconductors
  • Disclosures
    • Semiconductors
    • Energy
    • Bio & Healthcare
    • Defense
    • Shipbuilding
    • Automotive
  • Toggle search form
  • [Research] Samsung Electro-Mechanics (009150) – Shinhan Securities | High-Value Mix Expansion · MLCC High Utilization · Target P/B Upgrade / 2025-10-30 Semiconductors
  • [Disclosure] SK Square (402340) – Matters Related to Obligatory Fair Disclosure / 2024-03-28 Semiconductors
  • [Disclosure] Celltrion (068270) – Provisional Earnings Release (Consolidated Basis) (Correction) / 2025-11-04 Disclosures
  • [Disclosure] HPSP (403870) – Results of Annual General Meeting of Shareholders / 2025-03-28 Semiconductors
  • [Disclosure] Hanwha Ocean (042660) – (Correction) Decision on Guarantee for Others / 2025-03-20 Disclosures
  • [Disclosure] Hanwha Ocean (042660) – Decision on Debt Guarantee for Others / 2024-12-10 Disclosures
  • [Disclosure] Samsung Biologics (207940) – (Correction) Single Sales and Supply Contract / 2024-12-17 Disclosures
  • [Disclosure] Samsung Electronics (005930) – Decision on Disposal of Treasury Stock / 2026-01-29 Disclosures

[Disclosure] Celltrion (068270) – Decision on Acquisition of Treasury Shares / 2025-06-26

Posted on June 26, 2025August 6, 2026 By K-STOCK Editor

Fact Source: Financial Supervisory Service DART

💡 3-Second Summary

Celltrion has decided to acquire 623,053 common treasury shares (valued at approx. KRW 100.0B) through open market purchases to stabilize share prices and enhance shareholder value, with plans to fully cancel all acquired shares.

📊 [Key Disclosure Details & Financial Summary]

  • Disclosure Title: Decision on Acquisition of Treasury Shares
  • Number of Shares to be Acquired: 623,053 common shares (All shares to be canceled post-acquisition)
  • Estimated Total Acquisition Amount: KRW 100,000,006,500 (approx. KRW 100.0B / based on closing price of KRW 160,500 prior to Board decision, subject to market fluctuations)
  • Estimated Acquisition Period: June 27, 2025 ~ September 26, 2025
  • Purpose of Acquisition: Share price stabilization and enhancement of shareholder value
  • Method of Acquisition: On-market direct purchase on the KOSPI market
  • Entrusted Brokerage Firms: NH Investment & Securities Co., Ltd., Meritz Securities Co., Ltd.
  • Daily Buy Order Limit: 124,842 common shares
  • Board Resolution Date: June 26, 2025 (6 outside directors present, 2 absent)
  • Treasury Share Holdings Prior to Acquisition (As of 2025-06-26):
    • Acquired within dividend availability: 5,460,210 common shares (2.4%)
    • Other acquisitions: 5,004,851 common shares (2.2%)
    • Total Treasury Shares: 10,465,061 common shares
  • Remaining Treasury Share Acquisition Limit: KRW 4,480,424,805,318 (approx. KRW 4.48T)

📝 Editor’s Comment (Key Follow-up Checkpoint)

📌 Verification of Open-Market Buyback Execution and Subsequent Share Cancellation

This disclosure details Celltrion’s plan to acquire approx. KRW 100.0B in treasury shares on the open market and fully cancel them post-acquisition. It is key to monitor both the execution of open-market purchases during the scheduled buyback window (June 27 to September 26, 2025) and the subsequent board approval and execution of share cancellation. Tracking these steps ensures verification of reduced share count and shareholder return delivery. Final buyback results and retirement updates can be verified through the post-completion ‘Report on Results of Treasury Share Acquisition’, subsequent ‘Decision on Cancellation of Treasury Shares’ filings, or upcoming periodic reports (Quarterly, Half-Yearly, or Annual Business Reports).

📢 Disclaimer & Source Information

Source: This content was newly generated and structured based on official data submitted to the Data Analysis, Retrieval and Transfer System (DART) of the Financial Supervisory Service.

Investment Risk Notice: This information is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific stock. All investment decisions and financial responsibilities rest solely with the investor.

Contact: For compliance inquiries or copyright concerns, please contact ksb220805@gmail.com.

Search by
Company Name or Stock Ticker.
Disclosures, Bio & Healthcare

Post navigation

Previous Post: [Disclosure] Hanwha Systems (272210) – Corporate Value-up Plan / 2025-06-26
Next Post: [Research] SK hynix (000660 / SKHY) – Hyundai Motor Securities | HBM Growth Potential · Target P/B Upgraded · Blackwell Ultra Effect / 2025-06-26

Related Posts

  • [Disclosure] ALTEOGEN (196170) – Investor Relations (IR) Host / 2026-06-16 Disclosures
  • [Disclosure] Hanwha Ocean (042660) – Provisional Financial Results (Consolidated) / 2024-07-26 Disclosures
  • [Disclosure] Daeduck Electronics (353200) – Resolution on Board Decision to Convene Annual General Meeting of Shareholders / 2025-02-20 Semiconductors
  • [Disclosure] Samsung Electronics (005930) – Other Management Matters (Voluntary Disclosure) / 2025-10-30 Semiconductors
  • [Disclosure] HPSP (403870) – Decision on Cash and In-Kind Dividend / 2025-02-13 Semiconductors
  • [Disclosure] Samsung Electronics (005930) – (Correction) Long-term Business and Management Plan (Fair Disclosure) / 2026-06-29 Semiconductors
  • [Disclosure] Celltrion (068270) – Additional Listing (Bonus Issue) / 2026-06-25 Disclosures
  • [Research] Samsung Electro-Mechanics (009150) – Daishin Securities | MLCC Mix · FC-BGA · Glass Substrate / 2025-03-11 RESEARCH
  • [Disclosure] ISU PETASYS(007660) – Issue Price of New Shares for Rights Offering (Guidance Disclosure) / 2025-02-21 Semiconductors
  • [Disclosure] Hyundai Motor (005380) – Prospects on Business Performance / 2024-01-03 Disclosures
  • [Disclosure] Celltrion (068270) – Approval of European Commission Marketing Authorization for Stoboclo & Osenvelt (CT-P41, Prolia & Xgeva Biosimilars) / 2025-02-18 Disclosures
  • [Disclosure] Samsung Biologics (207940) – Result of Action Such as Prosecution Referral for Violation of Accounting Standards / 2025-07-17 Disclosures
  • [Research] Samsung Electro-Mechanics (009150) – Kyobo Securities | High-Value Non-IT Mix · 4Q Seasonality Overhaul · AI Cycle Beneficiary / 2025-10-30 RESEARCH
  • [Disclosure] Samsung Electro-Mechanics (009150) – Investor Relations (IR) Schedule Announcement / 2025-04-10 Semiconductors

Copyright © 2026 K-Stock Briefing.

Powered by PressBook News Dark theme